Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FAIR-HFpEF: IV Iron in HFpEF with Iron Deficiency
NCT03074591Phase 4Completed
- Sponsor
- Charité – Universitätsmedizin Berlin
- Start
- Aug 2017
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of ferric carboxymaltose in heart failure with preserved ejection fraction (HFpEF), iron deficiency anemia (IDA), sponsored by Charité – Universitätsmedizin Berlin. Started Aug 2017; status: completed.
02
Drugs
ferric carboxymaltose
03
Conditions
heart failure with preserved ejection fraction (HFpEF)iron deficiency anemia (IDA)
Beyond the preview
Go deeper on NCT03074591.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03074591.